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ttp://dx.doi.org/10.1016/j.ajpath.2013.10.013Estrogen and its nuclear receptor, estrogen receptor a, are necessary cofactors in the initiation and multi-
stage progression of carcinogenesis in the K14E6/E7 transgenic mouse model of human papillomaviruse
associated cervical cancer. Recently, our laboratory reported that raloxifene, a selective estrogen receptor
modulator, promoted regression of high-grade dysplasia and cancer that arose in the cervix of K14E6/E7
transgenicmice treated long-termwith estrogen. Herein, we evaluated the recurrence of cervical cancer after
raloxifene therapy in our preclinical model of human papillomaviruseassociated cervical carcinogenesis. We
observed recurrence of cervical cancer in mice re-exposed to estrogen after raloxifene treatment, despite
evidence suggesting the antagonistic effects of raloxifene persisted in the reproductive tract after treatment
had ceased. We also observed recurrence of neoplastic disease in mice that were not retreated with exog-
enous estrogen, although the severity of disease was less. Recurrent neoplastic disease and cancers retained
functional estrogen receptor a and responded to retreatment with raloxifene. Moreover, continuous treat-
ment of mice with raloxifene prevented the emergence of recurrent disease seen in mice in which raloxifene
was discontinued. These data suggest that cervical cancer cells are not completely eradicated by raloxifene
and rapidly expand if raloxifene treatment is ceased. These ﬁndings indicate that a prolonged treatment
period with raloxifene might be required to prevent recurrence of neoplastic disease and lower reproductive
tract cancers. (Am J Pathol 2014, 184: 530e540; http://dx.doi.org/10.1016/j.ajpath.2013.10.013)Supported by National Institute of Allergy and Infectious Diseases T32
training grant AI078985 (M.E.S.), Cancer Prevention and Research Insti-
tute of Texas Imaging Core seed grant RP120617 (S.-H.C.), and National
Cancer Institute grants CA022443, CA141583, and CA098428 (P.F.L.).Human papillomaviruses (HPVs), particularly those classi-
ﬁed as high-risk mucosal subtypes, are associated with
nearly all invasive cervical cancers.1 One high-risk geno-
type, HPV-16, is the most prevalent mucosal papillomavirus
and accounts for more than half of all cervical cancer cases.2
Cervical cancer incidence has decreased in developed
countries because of effective screening methods, and a
further decrease is expected after the introduction of pro-
phylactic vaccines, yet cervical cancer still accounts for 8%
of the global female cancer burden and remains the second
most common cancer in women.3 A lack of effective
treatment options, coupled with disproportionate access to
vaccination and screening worldwide, generates an ongoing
need for new cervical cancer therapeutics.
Although persistent HPV infections are necessary for the
development of HPV-associated cancers, they are not sufﬁ-
cient because only a fraction of patients with persistent in-
fections develop cervical cancer or even the high-gradestigative Pathology.
.precancerous lesions from which cervical cancer arises.4
Epidemiological data support a role for other factors that
range from smoking to insufﬁcient screening, but the two
most signiﬁcantly associated factors are multiparity and long-
term oral contraceptive use.5e8 Both of these variables are
associated with elevated levels of the female hormone,
estrogen, and their link to cervical cancer risk supports a
growing body of research from in vivo animal models that
identiﬁes a requirement for estrogen in HPV-induced cervical
carcinogenesis.9 A recent study found that patients with
HPV-associated cervical neoplasia have signiﬁcantly
heightened levels of one active form of estrogen, 16a-
hydroxyestrone, in their blood.10 In this same study, a
Cervical Disease after SERM Treatmentpositive, but not statically signiﬁcant, association also was
seen with circulating levels of estradiol. A positive associa-
tion of circulating estradiol levels with cervical cancer was
also reported in the larger and more recent European Pro-
spective Investigation into Cancer and Nutrition study.11
Estrogen was ﬁrst identiﬁed as a cofactor necessary for
squamous carcinogenesis in the K14-HPV16 transgenic
mouse model,12 and subsequent research revealed that the
hormone promotes a multistage process of neoplastic pro-
gression in the cervical transformation zone.13 The two main
HPV-16 oncogenes have individual functions in this
estrogen-induced neoplastic progression to cervical squa-
mous cell carcinoma, with E7 being the more potent onco-
gene and E6 acting to augment the malignant phenotype of
E7-induced tumors.14 Cervical cancers that arise in the mu-
rine reproductive tract in response to long-term estrogen
treatment are dependent on the continuous expression of E715
and require continuous exposure to exogenous estrogen for
growth and persistence.16,17 The requirement for estrogen is
reinforced by studies demonstrating that cervical cancer
development in HPV-transgenic mice is dependent on es-
trogen receptor a (ERa), with its expression in the underlying
stroma being critical.18,19 Taken together, the epidemiolog-
ical data and results from transgenic mouse model studies
provide compelling evidence for a synergistic relationship
between the HPV-16 E6 and E7 oncogenes and estrogen in
cervical cancer biogenesis, growth, and persistence.
The identiﬁcation of estrogen as a cocarcinogen in murine
models of HPV-associated cervical carcinogenesis previously
prompted our laboratory to determine the efﬁcacy of estrogen
receptor antagonists as a means of treatment for cancers that
arise after long-term estrogen exposure in HPV transgenic
animals. Indeed, treatment of established squamous cell
carcinomas of the lower reproductive tract with either the
complete ERa antagonist, fulvestrant (ICI 182,780), or the
selective estrogen receptor modulator (SERM), raloxifene,
was highly efﬁcient in promoting cancer regression.17
Furthermore, treatment of precancerous lesions with fulves-
trant prevented further disease progression and inhibited the
onset of lower reproductive tract cancers. Considering the
signiﬁcant implications to human health, we were further
motivated to investigate if the cancer recurs after drug treat-
ment. In this study, we examined the recurrence of lower
reproductive tract cancers after treatment with raloxifene. We
found that neoplastic disease recurs after cessation of treat-
ment with raloxifene, regardless of exogenous estrogen,
although it did increase the severity of the recurrent neoplastic
disease. All recurrent cancers retained an active estrogen/ERa
signaling pathway and were responsive to retreatment with
raloxifene.Maintainingmice on raloxifene prevented the high
recurrence rates of cancer. We hypothesize that residual
cancer cells drive cancer recurrence in mice upon release from
treatment with raloxifene. This study supports the premise
that SERMs, such as raloxifene, may be effective in treating
HPV-associated human cervical cancers, but that their effec-
tiveness may require long-term treatment.The American Journal of Pathology - ajp.amjpathol.orgMaterials and Methods
Transgenic Mice and Hormone Treatment
The K14E7 and K14E6 transgenic mouse lines were main-
tained on the FVB/n inbred genetic background and have
been described previously.20,21 At 4 to 6 weeks of age,
K14E6/K14E7 (referred to as K14E6/E7 herein) double
transgenic virgin females were anesthetized with 5% iso-
ﬂurane, and a continuous-release estrogen (E2) tablet (17b-
estradiol; 0.05 mg/60 days; Innovative Research of America,
Sarasota, FL) was inserted s.c. in the shoulder fat pads of the
dorsal skin. A new tablet was inserted every 2 months as
needed. Mice were housed in the American Association of
Laboratory Animal Careeapproved McArdle Laboratory
Animal Care Unit of the University of Wisconsin School of
Medicine and Public Health (Madison, WI). All procedures
were performed according to a protocol approved by the
University of Wisconsin Institutional Animal Care and Use
Committee.
Drug Treatment
Treatment of mice with raloxifene was performed as
previously described.17 Brieﬂy, the human formulation of
raloxifene hydrochloride (60 mg tablets; EVISTA; Eli Lilly,
Indianapolis, IN) was purchased from the University of Wis-
consin Hospital Pharmacy. Tablets were resuspended in PBS
at a ﬁnal concentration of 10 mg/mL. Mice were administered
a 150-mL drug suspension (equivalent to 1.5 mg) by i.p. in-
jection at each treatment. The duration of treatment was 4
weeks (5 days a week) for a total of 20 treatments. Treatment
with raloxifene did not increase morbidity or mortality.
Tissue Procurement and Disease Scoring
One hour before sacriﬁce, mice were treated with 100 mg/kg
5-bromodeoxyuridine (BrdU) by i.p. injection. Reproduc-
tive tracts were harvested, ﬁxed in 4% paraformaldehyde,
and embedded in parafﬁn. Serial sections (5 mm thick) were
cut and every 10th section was stained with H&E.
H&E-stained sections were evaluated for histopathological
features and scored for worst disease, according to the his-
topathological grading system outlined by Riley et al.14
Images of H&E-stained cervical tumors and epithelia were
captured using a Zeiss AxioImager M2 microscope and
AxioVision software version 4.8.2 (Jena, Germany).
IHC Data
Sections were deparafﬁnized and rehydrated with xylenes and
graded ethanol, respectively. Endogenous peroxidase activity
was quenched with 3% H2O2 in methanol and followed with
heat-induced antigen retrieval in 10 mmol/L citrate buffer (pH
6.0). Antibodies used include anti-BrdU (Calbiochem, Bill-
erica, MA), antiemini-chromosome maintenance protein 7
(MCM7) (ThermoScientiﬁc, Fremont, CA), anti-progesterone531
Spurgeon et alreceptor (PR; Santa Cruz Biotechnology, Santa Cruz, CA),
anti-ERa (Santa Cruz Biotechnology), and biotinylated horse
anti-mouse/rabbit IgGs (Vector Laboratories, Burlingame,
CA). Proteins were visualized with 3,30-diaminobenzidine
(Vector Laboratories), and tissues were counterstained with
hematoxylin. All images were taken with a Zeiss AxioImager
M2 microscope using the AxioVision software version 4.8.2.
Tumor Measurement and BrdU Quantitation
Tissues were ﬁrst H&E stained and then tumor images were
captured with a Zeiss AxioImager M2 microscope ﬁtted
with a 2.5 objective. By using the AxioVision software
version 4.8.2, the total area of each tumor was measured by
tracing the tumor boundaries. Manual pixel-to-micrometer
conversions were not necessary, because this conversion is
automatically conﬁgured for each microscope objective
using the AxioVision software version 4.8.2. For tumors
spanning more than one ﬁeld of view, the sum of tumor
areas from contiguous images was calculated.
For BrdU quantitation, representative slides were processed
for immunohistochemistry (IHC), as previously described. For
each group, one slide from three individual mice was analyzed
by microscopy andmultiple 20 images (5 to 10 per mouse) of
the cervical epithelium or cervical cancers were captured. The
total number of cells and the number ofBrdU-positive cellswere
quantiﬁed with an automated cell counting program [David
Ornelles (WakeForestUniversitySchool ofMedicine,Winston-
Salem, NC)] using ImageJ software version 1.47 (NIH,
Bethesda, MD; unpublished data). The percentage of BrdU-
positive cells was calculated using the two resulting values.
Statistical Analysis
The two-sided Fisher’s exact test was used for analyses
comparing cancer incidence, incidence of multiple tumors,
and incidence of large tumors. For statistical analyses
comparing disease severity, tumor multiplicity, tumor size,
and BrdU quantitation, the two-sidedWilcoxon rank sum test
was used. When comparing overall disease severity using the
Wilcoxon rank sum test, each lesion was given an arbitrary
score (rank) before analysis: no disease, 0; cervical intra-
epithelial neoplasia (CIN)/vaginal intraepithelial neoplasia
(VIN) 1, 1; CIN/VIN2, 2; CIN/VIN3, 3; and cancer, 4. All
statistical analyses were performed using MSTAT statistical
software version 5.5.7 (http://www.mcardle.wisc.edu/mstat,
last accessed October 5, 2013).
Results
Selection of Raloxifene for Recurrence Studies and
Clearance from the Murine Reproductive Tract
Prior attempts were made to experimentally address the issue
of cancer recurrence after cessation of fulvestrant treat-
ment.17 However, these experiments evaluated for recurrence532only 6 weeks after termination of ERa antagonist treatment.
Although no tumors recurred in these mice, this time frame
was not sufﬁcient to allow for clearance of fulvestrant effects
in the reproductive tract, preventing our ability to assess
cancer recurrence in the absence of effects of the drug. In the
study reported herein, we evaluated cancer recurrence after
cessation of treatment with raloxifene, an SERM that was
equally effective at promoting cancer regression, in which we
extended the recurrence evaluation to 12 weeks after termi-
nation of SERM treatment.
To our knowledge, the pharmacokinetics of raloxifene in
the lower reproductive tract of mice have not been systemat-
ically evaluated. Therefore, we sought to determine the length
of time required for clearance of overt anti-estrogenic pheno-
types of raloxifene in the murine reproductive tract. Female,
non-transgenic FVB/n mice were separated into two groups:
one group received a 1-month raloxifene treatment identical to
that used in the recurrence study, and the other group received
no treatment. Both groups of mice were then treated with
exogenous estrogen, and a contingent of mice was sacriﬁced,
reproductive tracts were collected, and wet weights were
measured every 2 weeks for a total of 3 months (Supplemental
Figure S1). In mice that were not treated with raloxifene, the
reproductive tract wet weight increased within 2 weeks and
remained elevated for the remainder of the 3-month estrogen
treatment period (Supplemental Figure S1A). In contrast, the
increase in the reproductive tract wet weight in mice treated
with raloxifene before exogenous estrogen exposure was
substantially delayed and did not appear until 10 weeks after
cessation of raloxifene treatment (Supplemental Figure S1B).
The cervical epithelium in those mice never treated with ral-
oxifene displayed a physiological hyperplasia by 2 weeks of
estrogen treatment, yet the same was not seen in those mice
previously treated with raloxifene until approximately 10
weeks (Supplemental Figure S1C). The cervical epithelium of
mice treated with raloxifene was hypoplastic and displayed a
loss of differentiation consistent with previous observations of
ERa inhibition,17,19 and this phenotype persisted for 10weeks.
Indeed, the appearance of cells positive for an ERa tran-
scriptional target, PR, was concomitant with the increase in
reproductive tract wet weight and the appearance of hyper-
plastic epithelium in both treatment groups (Supplemental
Figure S1C), suggesting these results are a legitimate reﬂec-
tion of raloxifene persistence in the murine reproductive tract.
Cervical Cancers Recur after Raloxifene Treatment
Because the effects of raloxifene disappeared somewhere
between 8 and 10 weeks after cessation of treatment, we
chose to evaluate cancer recurrence 3 months after cessation
of raloxifene therapy. Mice are approximately 1 year old at
this end point, making it difﬁcult to extend these studies
much longer because of morbidity issues associated with the
HPV16 E7 transgene that are unrelated to the female
reproductive tract (eg, apnea arising from thymic hyper-
plasia and bladder distention by exogenous estrogen).ajp.amjpathol.org - The American Journal of Pathology
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Groups of female, virgin K14E6/E7 transgenic mice were
administered various regimens of exogenous estrogen and
raloxifene treatment (Figure 1A). A histopathological anal-
ysis was performed on reproductive tract tissue sections
from these mice to score for disease severity (Table 1) and
cancer incidence (Figure 1B). Disease severity was deter-
mined by comparing the overall incidence of precancerous
(CIN1 to CIN3) and cancerous lesions in each group.
Treating mice with estrogen for 6 months (E26m) induces
the development of high-grade dysplasia and squamous cell
carcinoma in the lower reproductive tract.13,14,16,17 Archival
data from our recent publication are consistent with these
ﬁndings, such that squamous cell carcinomas developed in
the cervix of all K14E6/E7 transgenic mice (six of six) and
in the vagina of half of the mice (three of six).17 Any
pathological feature that arises in this group of mice is
henceforth considered initial disease. Another group of mice
was treated with exogenous estrogen for 6 months to induce
initial disease and subsequently treated with raloxifene for 1
month (E26m/Ral1m). Both cancer incidence (P Z 0.0006)
and disease severity (P Z 0.0004) were signiﬁcantly
reduced in the cervix; similar results were observed in theFigure 1 Cancers of the lower reproductive tract recur after raloxifene treat
regimens used to determine disease recurrence after raloxifene therapy. Black arro
treatment. Vertical dashed lines indicate treatment duration. B: End point cancer
regimens. Statistical comparisons between groups are noted in the text. For num
images of H&E-stained endocervical sections from the indicated treatment groups
and low-magniﬁcation images of the cervical region and cervical cancers, where
basement membrane in the high-magniﬁcation images. Scale bars: 100 mm.
The American Journal of Pathology - ajp.amjpathol.orgvagina (incidence P Z 0.029, severity P Z 0.0008). This
level of cancer regression in response to raloxifene was
nearly identical to our prior study.17
To monitor recurrence of cancer after cessation of ral-
oxifene treatment, another group of mice (n Z 11) was
treated with exogenous estrogen for 6 months and raloxifene
for 1 month to induce initial carcinogenesis and cancer
regression, respectively, and then retreated with exogenous
estrogen for an additional 3 months (E26m/Ral1m/E23m). In
these animals, a high incidence of lower reproductive tract
cancers was observed: 8 (73%) of 11 mice had cervical
cancer and 7 (64%) of 11 mice had vaginal cancer, repre-
senting a signiﬁcant increase in both cancer incidence and
disease severity compared with E26m/Ral1m mice (cervix:
incidence P Z 0.008 and severity P Z 0.0001; vagina:
incidence P Z 0.004 and severity P Z 0.0002). The inci-
dence of lower reproductive tract cancers and disease
severity in the E26m/Ral1m/E23m mice were comparable to
those observed in the E26m mice (incidence P Z 0.27 and
severity P Z 0.17).
To determine whether the cancers found in the E26m/Ral1m/
E23m mice originated from initial tumors that had developed
after the initial 6 months of estrogen treatment, and were notment and do not require exogenous estrogen. A: Schematic of treatment
ws indicate treatment with estrogen or raloxifene; gray arrows, absence of
incidence in groups of mice administered different E2/raloxifene treatment
bers of mice per group and disease severity, see Table 1. C: Representative
. High-magniﬁcation images of the cervical squamous epithelium (top row)
applicable (bottom row), are shown. A black line is used to highlight the
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Table 1 Summary of Disease Recurrence in K14E6/E7 Transgenic Mice after Raloxifene Treatment
Treatment group
Group
size (n)
No disease,
cervix (vagina)
Dysplasia only Cancer and dysplasia,
cervix (vagina)CIN1 (VIN1) CIN2 (VIN2) CIN3 (VIN3)
E26m* 6 0 (0) 0 (0) 0 (1) 0 (2) 6 (3)
E26m/Ral1m 11 10 (9) 0 (0) 0 (1) 0 (1) 1 (0)
No E26m/Ral1m/E23m 12 1 (0) 4 (3) 6 (9) 0 (0) 1 (0)
E26m/Ral1m/E23m 11 0 (0) 1 (1) 1 (3) 1 (0) 8 (7)
E26m/Ral1m/NoE23m 10 3 (2) 3 (4) 0 (2) 0 (0) 4 (2)
Mice were scored histopathologically for the worst disease present in the cervix and vagina (in parentheses). For statistical comparisons between groups, please
refer to the text in the Results sections Cervical Cancers Recur after Raloxifene Treatment and Role of Exogenous Estrogen in Re-Emergence of Neoplastic Disease.
*Archival data from Chung and Lambert.17
CIN, cervical intraepithelial neoplasia; VIN, vaginal intraepithelial neoplasia.
Spurgeon et althe product of de novo tumorigenesis, an additional control
group of mice was analyzed. These mice received no estrogen
for the initial 6 months but did receive raloxifene treatment,
followed by 3 months of exogenous estrogen (NoE26m/Ral1m/
E23m). Three months of exogenous estrogen exposure is rarely
sufﬁcient to promote tumor development in the cervix of
K14E6/E7 mice.12,13,17 Correspondingly, the cervical epithe-
lium in mice from this NoE26m/Ral1m/E23m treatment group
primarily contained low to moderate dysplasia, and only 1
(8%) of 12 mice developed a cervical tumor. The disease
severity and the incidence of cancer observed in the E26m/
Ral1m/E23m mice were signiﬁcantly higher than those
observed in the NoE26m/Ral1m/E23m mice (all comparisons
P < 0.004). Together, these observations indicate that lower
reproductive tract cancers recur in K14E6/E7 transgenic mice
administered exogenous estrogen again after cessation of ral-
oxifene therapy. These results also imply that initial tumor
cells were not completely eliminated by the 1-month treatment
with raloxifene.
Role of Exogenous Estrogen in Re-Emergence of
Neoplastic Disease
To determine whether recurrence of neoplastic disease
requires exogenous estrogen, an additional group of mice
(n Z 10) treated for 6 months with estrogen, followed by
1-month treatment with raloxifene, was held for 3 months
without retreatment with exogenous estrogen (E26m/Ral1m/
NoE23m) (Figure 1A). Neoplastic disease recurred in the
lower reproductive tracts of these mice (Table 1 and
Figure 1B). Cervical and vaginal cancers were present in
40% (4 of 10) and 20% (2 of 10) of mice, respectively. The
incidence of cancer was not signiﬁcantly different from that
observed in the E26m/Ral1m mice (P > 0.15), which could
suggest that the cancers found in the E26m/Ral1m/NoE23m
mice reﬂect tumors that did not respond to raloxifene.
However, the overall severity of disease, which accounts for
the frequency of precancerous and cancerous lesions, was
signiﬁcantly worse in both the cervix and vagina (P <
0.018). This ﬁnding indicates that at least precancerous le-
sions recur upon cessation of raloxifene treatment and in
the absence of re-exposure to exogenous estrogen. The534incidence of cancer and disease severity within the cervix of
the E26m/Ral1m/NoE23m mice remained signiﬁcantly lower
than initial disease observed in the E26m mice (P Z 0.034
and P Z 0.024, respectively), whereas in the vagina, the
incidence of cancer was not signiﬁcantly different but
overall disease severity was signiﬁcantly lower (P Z
0.026). To assess further the inﬂuence of exogenous estro-
gen on recurrence of lower reproductive tract neoplastic
disease, we compared the cancer incidence and disease
severity in the E26m/Ral1m/E23m and E26m/Ral1m/NoE23m
cohorts. There was no difference in cancer incidence (cervix
P Z 0.198, vagina P Z 0.08); however, the mice retreated
with exogenous estrogen exhibited more severe disease
(cervix P Z 0.045, vagina P Z 0.014). Based on these
initial comparisons, we conclude that re-emergence of
neoplastic disease within the lower female reproductive tract
after release from raloxifene treatment is not absolutely
dependent on exogenous estrogen, but the severity of the
recurrent neoplasia is clearly greater when mice are re-
exposed to estrogen.
Histopathological Characteristics of Recurrent Cervical
Disease and Cancers
We next sought to evaluate and compare the cervical his-
topathological characteristics in mice from the various
treatment groups (Figure 1C). In mice retreated with exog-
enous estrogen after cessation of raloxifene treatment (E26m/
Ral1m/E23m), the stratiﬁed squamous cervical epithelium
reverted from a hypoplastic, undifferentiated phenotype
associated with SERM treatment (E26m/Ral1m) to a thick,
hyperplastic epithelium with papillomatosis similar to that
observed in the cervices of mice in the E26m treatment
group. On the other hand, although the cervical epithelium
in mice not retreated with exogenous estrogen (E26m/Ral1m/
NoE23m) was hyperplastic compared with the epithelium
after cessation of raloxifene treatment (E26m/Ral1m group),
it did not revert to the E26m phenotype to the same extent as
seen in the E26m/Ral1m/E23m mice. A moderate portion of
the cervical epithelium in the E26m/Ral1m/NoE23m cohort
retained histological features seen in the E26m/Ral1m mice,
such as loss of differentiation and a generally thinnerajp.amjpathol.org - The American Journal of Pathology
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the endocervix (data not shown). However, the increased
thickness compared with the E26m/Ral1m mice suggests that
these mice did return to normal estrus cycling by the end
point. These histopathological traits of the cervical epithe-
lium in mice from the E26m/Ral1m/NoE23m treatment group
may help explain the reduced disease severity observed
compared with initial disease and disease that recurs in the
presence of exogenous estrogen (Table 1). Although these
minor differences existed in the stratiﬁed squamous
epithelium, the histological characteristics of initial and
recurrent squamous cell carcinomas were largely compara-
ble. Most recurrent cancers were reasonably well organized
and developed in the outer cervix or at the cervicovaginal
junction, regardless of whether the mice were retreated with
exogenous estrogen (data not shown). Therefore, any major
differences between initial and recurrent tumors, or between
tumors arising in the presence and absence of exogenous
estrogen after cessation of raloxifene treatment, were not
evident at the level of tissue histopathological features.
Recurrent Cancers Are More Proliferative in Mice
Retreated with Exogenous Estrogen after Cessation of
Raloxifene Treatment, and Proliferation of the Cervical
Epithelium Is a Predictor of Cancer Recurrence
After cessation of raloxifene treatment, we observed cervical
cancer in the presence and absence of estrogen (Table 1).
However, cervical cancers re-emerged with an incidence
similar to initial cancer, and disease was generally more severe
in mice administered exogenous estrogen again (Figure 1B).
To determine whether the cervical tumors and epithelium in
mice retreated with exogenous estrogen were more prolifera-
tive than in non-treated mice, the proliferative indices of in-
dividual cancers were scored by counting the number of cells
that incorporated BrdU into their DNA. Recurrent cervicalThe American Journal of Pathology - ajp.amjpathol.orgtumors in mice retreated with exogenous estrogen had a
signiﬁcantly higher average percentage of BrdU-positive cells
than the cervical tumors in mice not retreated with exogenous
estrogen (11.9% versus 7.9%; PZ 0.05) (Figure 2A). How-
ever, this difference in recurrent tumor proliferation could not
be explained by an inherent increase in the proliferative index
of the cervical epithelium in mice retreated with exogenous
estrogen (PZ 0.13) (Figure 2B).
We further evaluated if the proliferative index of the
epithelium was predictive of cancer recurrence. For this
analysis, we compared BrdU incorporation in the cervical
epithelia of mice within each treatment group between those
animals that developed recurrent cervical cancers and those
that did not. Regions of epithelium both proximal and distal to
tumors were included in the analysis of mice with recurrent
tumors to accurately measure proliferation throughout the
entire cervix. The cervical epithelium in mice that developed
recurrent cervical tumors had a signiﬁcantly higher average
percentage of BrdU-positive cells than the cervical epithelium
in mice that were tumor-free in both the E26m/Ral1m/E23m
group (12.2% versus 6.6%; P Z 0.05) and the E26m/Ral1m/
NoE23m group (9.6% versus 3.5%; P Z 0.05) (Figure 2B).
Overall, these data indicate that cell proliferation in the cer-
vical epithelium positively correlates with the presence of
recurrent cervical tumors after cessation of raloxifene therapy.
Exogenous Estrogen Increases the Multiplicity, But Not
Size, of Recurrent Cervical Tumors in Mice after
Raloxifene Treatment
To learn more about cervical cancer recurrence in the
presence and absence of exogenous estrogen, we compared
the multiplicity and size of the tumors in the E26m/Ral1m/
E23m and E26m/Ral1m/NoE23m treatment groups, as well as
other cancer development characteristics. In the presence of
exogenous estrogen, recurrent cervical tumors developedFigure 2 Proliferation of the cervical epithe-
lium is a predictor of cancer recurrence. A:
Representative images showing BrdU IHC results in
recurrent cervical tumors and quantitation of the
average percentage of BrdU-positive cells in the
cervical epithelium of tumors. For each treatment
group, three mice from each condition were
included for analysis. Positive cells were quantiﬁed
from 5 to 10 image ﬁelds captured from all areas of
the cervix using an automated counting program
designed for ImageJ software version 1.47 (see
Materials and Methods). Statistical comparisons are
discussed in the text. Error bars Z SD. B:
Representative images of BrdU IHC showing the
cervical epithelium of mice with recurrent tumors
(black bars) or free of recurrent tumors (gray bars).
A black line is used to highlight the basement
membrane. Quantiﬁcation was performed and dis-
played as described in A. Scale bars: 100 mm (A
and B).
535
Spurgeon et alwith an approximately threefold greater multiplicity than in
the absence of estrogen treatment (1.36  1.12 versus 0.4 
0.52; P Z 0.036) (Figure 3A). Similar results were also
observed for recurrent vaginal cancers (1.09  1.04 versus
0.3  0.67; P Z 0.049) (Figure 3A). Despite these differ-
ences, retreatment with exogenous estrogen did not signif-
icantly affect cervical tumor size (Figure 3B). Tumors in the
E26m/Ral1m/E23m mice had a mean size of 1.29  1.34 mm2
compared with 1.45  1.44 mm2 in the E26m/Ral1m/NoE23m
mice (P Z 0.689). The largest recurrent cervical tumor
measured in mice from the E26m/Ral1m/E23m treatment
group was 4.39 mm2, and 3.50 mm2 in the E26m/Ral1m/Figure 3 Exogenous estrogen increases the multiplicity of recurrent
cervical tumors after raloxifene treatment. A: The multiplicity of recurrent
tumors in the cervix and vagina is shown. Results are shown as means  SD.
P< 0.05 as determined by a two-sided Wilcoxon rank sum test. B: Distribution
of recurrent cervical tumor sizes is shown. Individual tumor values are shown
as black circles, and the average tumor size for the group of mice is shown as a
horizontal black line. C: Low-magniﬁcation images of representative H&E-
stained tissue sections highlighting recurrent tumors in the outer cervix and
cervicovaginal region. Scale bars: 200 mm.
536NoE23m group. Similar results were seen in the vagina of
the E26m/Ral1m/E23m and E26m/Ral1m/NoE23m mice
(2.46  2.38 mm2 versus 1.17  1.14 mm2; P Z 0.67), in
which the largest tumors were 6.791 and 2.48 mm2,
respectively. Representative images of recurrent cervical
tumors from H&E-stained endocervical sections showed the
presence of large, recurrent tumors in both groups of mice
after cessation of raloxifene therapy (Figure 3C), corrobo-
rating the ﬁnding that large tumors can re-emerge even in
the absence of exogenous estrogen.
To evaluate the effect of exogenous estrogen on overall
cancer phenotype within the entire cervicovaginal region,
data from the cervix and vagina were combined (Table 2).
Although the cancer incidence in the lower reproductive
tract was higher in the E26m/Ral1m/E23m group of mice
compared with the E26m/Ral1m/NoE23m group (82% versus
40%), it was not statistically signiﬁcant (P Z 0.08).
Nonetheless, the proportion of mice that developed multiple
recurrent tumors in the cervicovaginal region increased 3.7-
fold in the presence of exogenous estrogen compared with
untreated mice after cessation of raloxifene therapy (73%
versus 20%; P Z 0.03). On average, mice that were re-
exposed to exogenous estrogen also had 3.5-fold more tu-
mors in the lower reproductive tract than their untreated
counterparts (2.45  1.57 versus 0.7  1.06; P Z 0.01).
These ﬁndings are consistent with data obtained from the
cervix and vagina separately (Figure 3A). Finally, treatment
with exogenous estrogen did not signiﬁcantly increase the
proportion of mice with recurrent tumors >2 mm2 when
compared with untreated mice after cessation of raloxifene
therapy (44% versus 25%; PZ 1.0). This ﬁnding is similar
to data that showed exogenous estrogen does not signiﬁ-
cantly affect recurrent tumor size (Figure 3B). Taken
together, we conclude that recurrent cancer burden is higher
in mice retreated with exogenous estrogen after cessation of
raloxifene therapy compared with mice not retreated with
estrogen.
Recurrent Tumors Exhibit a Similar Pattern of
Biomarker Expression as Initial Tumors and Retain ERa
Expression and Function
In addition to cancer characteristics, we also sought to
evaluate the stratiﬁed squamous epithelium and tumors in
the cervices of mice with recurrent cancers for expression of
pertinent biomarkers. The MCM7 protein is an E2F-induced
cellular protein involved in DNA replication that was pre-
viously identiﬁed as a biomarker of cervical cancer.22
Strong IHC positivity for MCM7 throughout all layers of
stratiﬁed squamous epithelium is associated with high-grade
dysplastic lesions and tumors of the cervix. The cervical
epithelia of mice in the E26m, E26m/Ral1m/E23m, and E26m/
Ral1m/NoE23m treatment groups all had strong MCM7
staining throughout the basal and suprabasal layers
(Figure 4A). Interestingly, mice from the E26m/Ral1m/
NoE23m treatment group had a low, but consistent, level ofajp.amjpathol.org - The American Journal of Pathology
Table 2 Summary of Recurrent Cancer Characteristics in the Lower Reproductive Tracts of K14E6/E7 Transgenic Mice after Raloxifene
Treatment
Treatment group
Group
size (n)
No. (%) of mice
with cancer*
No. (%) of mice
with multiple cancersy
Mean No. of
tumorsy
No. (%) of mice
with cancers >2 mm2z
E26m/Ral1m/E23m 11 9 (82) 8 (73) 2.45  1.57 4 (44)
E26m/Ral1m/NoE23m 10 4 (40) 2 (20)x 0.70  1.06{ 1 (25)
For statistical comparisons between groups, please refer to the text in the Results section Exogenous Estrogen Increases the Multiplicity, But Not Size, of
Recurrent Cervical Tumors in Mice after Raloxifene Treatment.
*Determined for cervix and vagina combined.
yPer total number of mice in group.
zPer mice with cancer.
xP < 0.05 compared with E26m/Ral1m/E23m using a two-sided Fisher’s exact test.
{P < 0.05 compared with E26m/Ral1m/E23m using a two-sided Wilcoxon rank sum test.
Cervical Disease after SERM Treatmentdeviation from this staining pattern; MCM7-positive cells
were restricted to the basal layer within patches of the cer-
vical epithelium (data not shown). No other mice displayed
this pattern of MCM7 expression, and it is not understood
why this phenotype was only evident in mice from the
E26m/Ral1m/NoE23m treatment group. Nevertheless, all tu-
mors that re-emerged after cessation of raloxifene therapy
stained positively for MCM7 (Figure 4B). The pattern of
MCM7 staining in the cervical epithelium and tumors of
mice with recurrent cancer was similar to that seen in mice
with initial tumors (E26m).The American Journal of Pathology - ajp.amjpathol.orgIt was important to verify the expression and function of
ERa, because this receptor was previously found to be
necessary for cervical cancer development in the K14E7
transgenic mouse model.19 Therefore, IHC analysis was
performed for ERa and one of its transcriptional target
genes, PR, in the cervical epithelium and cancer of mice
from each treatment group. As shown in Figure 4A, ERa
was expressed throughout the stratiﬁed squamous epithe-
lium and underlying stroma of mice from all groups
analyzed. Regarding the functional capacity of ERa, the
cervical epithelium of mice from all treatment groupsFigure 4 Recurrent tumors and initial tumors exhibit a
similar pattern of biomarker expression. A: High-
magniﬁcation images of the cervical epithelium from
mice on various treatment regimens. IHC was performed
for the biomarkers MCM7, ERa, and PR on tissue sections.
A black line is used to highlight the basement membrane.
B: Recurrent cervical tumors with the same IHC analysis
performed as in A. Scale bars: 100 mm.
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Table 3 Summary of Disease in Additional Treatment Groups Testing Models of Cervical Cancer Recurrence
Treatment group
Group
size (n)
No disease,
cervix
(vagina)
Dysplasia only Cancer and
dysplasia,
cervix (vagina)
No. of mice
with cervical cancer
(cervical cancer incidence)
CIN1 (VIN1) CIN2 (VIN2) CIN3 (VIN3)
E26m/Ral1m/E23m/Ral1m 6 6 (6) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
E26m/Ral1m/NoE23m/Ral1m 3 3 (3) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
E26m/Ral4m 8 6 (6) 1 (1) 0 (0) 0 (0) 1 (1) 1 (12.5)
Mice were scored histopathologically for the worst disease present in the cervix and vagina (in parentheses). Cervical cancer incidence is compared with
values of cervical cancer incidence in treatment groups shown in Table 1. All statistical comparisons noted were obtained using a two-sided Fisher’s exact test.
For statistical comparisons between groups, please refer to the text in Results sections Recurrent Neoplastic Disease and Cancers Remain Responsive to Raloxifene
and Sustained Initial Treatment with Raloxifene Prevents Tumor Recurrence.
CIN, cervical intraepithelial neoplasia; VIN, vaginal intraepithelial neoplasia.
Spurgeon et alstained positive for the estrogen-responsive gene, PR,
except for those from the E26m/Ral1m group (Figure 4A).
These results verify that treatment with raloxifene efﬁciently
suppressed ERa function during our experiments and
demonstrate that mice regained ERa function by 3 months
after cessation of raloxifene treatment. The latter observa-
tion correlates with the histopathological characteristics of
the cervical epithelium for mice in the NoE26m/Ral1m/E23m,
E26m/Ral1m/E23m, and E26m/Ral1m/NoE23m treatment
groups (Figure 1C), all of which regain hyperplastic
epithelia. Similarly, all recurrent tumors stained positive by
IHC for ERa and PR (Figure 4B), regardless of whether the
tumors re-emerged in mice that did or did not receive
additional exogenous estrogen after raloxifene treatment.
We also evaluated expression of ERa and PR in the cervical
stroma because stromal ERa is required for cervical carci-
nogenesis.18 ERa and PR were stained positive in the
stroma associated with cancer (Figure 4B) and that distant
from cancer (data not shown). Taken together, these data
indicate that the ERa is both present and functional in the
cervical epithelium, tumors, and tumor-associated stroma of
mice that develop recurrent cancers after cessation of
treatment with raloxifene.
Recurrent Neoplastic Disease and Cancers Remain
Responsive to Raloxifene
The fact that recurrent cancers retained functional ERa led
us to assess whether they remained responsive to the ERa
antagonist, raloxifene. Two groups of HPV16 transgenic
mice were studied (E26m/Ral1m/E23m/Ral1m and E26m/
Ral1m/NoE23m/Ral1m). Both were initially treated with
exogenous estrogen for 6 months to induce cervical cancers,
and then treated with raloxifene for 1 month to cause
regression. One group (E26m/Ral1m/E23m/Ral1m; n Z 6)
was then retreated with estrogen for 3 additional months,
whereas the other group (E26m/Ral1m/NoE23m/Ral1m; n Z
3) was not re-exposed to estrogen for 3 additional months,
to allow cancers to recur. Both groups of mice were then
retreated with raloxifene for 1 month. At the end of this
retreatment with raloxifene, female reproductive tracts were
harvested and scored for disease (Table 3). None of the mice
from either group developed cancers. The histopathological538features of the cervix and vagina were indistinguishable
from those seen in the E26m/Ral1m mice, such that there was
an absence of any neoplastic lesions of any grade, and the
cervical/vaginal epithelia were hypoplastic (data not
shown). In the case of the E26m/Ral1m/E23m/Ral1m group,
the reduction in both cancer incidence and severity of dis-
ease compared with E26m/Ral1m/E23m mice was signiﬁcant
for both the cervix (P Z 0.009 and P Z 0.0003, respec-
tively) and the vagina (P Z 0.009 and P Z 0.0004,
respectively). The lack of cancers in the smaller E26m/
Ral1m/NoE23m/Ral1m group did not reach statistical signif-
icance compared with the E26m/Ral1m/NoE23m mice,
although the severity of disease was signiﬁcantly less in the
vagina (PZ 0.03) and nearly signiﬁcant in the cervix (PZ
0.06) in the raloxifene-retreated group. Although the sizes
of these study groups were small compared with other study
groups because of the previously mentioned age-related
morbidity issues, the complete absence of neoplastic dis-
ease in all nine mice retreated with raloxifene is strongly
suggestive that recurrent tumors and their precursor lesions
remain responsive to anti-estrogen therapy.
Sustained Initial Treatment with Raloxifene Prevents
Tumor Recurrence
Given that recurrent tumors remain responsive to raloxifene,
we then asked if keeping mice on raloxifene could prevent
recurrent disease from arising altogether. A group of
K14E6/E7 (n Z 8) mice was treated with estrogen for a
period of 6 months to induce dysplasia and cancer, and then
these mice were treated for 4 months with raloxifene (E26m/
Ral4m). Female reproductive tracts were then harvested and
histopathologically scored for disease (Table 3). Six of the
eight mice in this group had no disease at all. One retained a
cervical cancer, whereas another retained low-grade CIN.
Similar results were seen in the vagina. These ﬁndings were
similar to that observed in the E26m/Ral1m cohort (Table 1),
both in terms of incidence of cancer and severity of disease
in the cervix (P Z 1.0 and P Z 0.4, respectively) and the
vagina (PZ 0.4 and PZ 0.7, respectively). These ﬁndings
suggest that recurrent cancers and other precancerous le-
sions that arise when raloxifene is discontinued in mice (ie,
that seen in the E26m/Ral1m/E23m and E26m/Ral1m/NoE23majp.amjpathol.org - The American Journal of Pathology
Cervical Disease after SERM Treatmentgroups) are not arising because they acquired resistance to
the SERM. Further analysis of the data indicates that there
were signiﬁcant differences in the incidence of cancer and
severity of diseases between the E26m/Ral4m and E26m/
Ral1m/E23m groups of mice in both the cervix (P Z 0.02
and PZ 0.001, respectively) and the vagina (PZ 0.02 and
P Z 0.002, respectively), but such differences between the
E26m/Ral4m and E26m/Ral1m/NoE23m groups did not reach
signiﬁcance, except in the case of severity of disease in the
vagina (P Z 0.05). These results are similar to the com-
parisons made between the E26m/Ral1m group of mice and
the two groups in which raloxifene was discontinued (E26m/
Ral1m/E23m and E26m/NoRal1m/E23m).Discussion
Our study demonstrates that treatment of cervical cancers in
K14E6/E7 mice with the ERa antagonist, raloxifene, fails to
completely eliminate neoplastic cells, because our ﬁndings
indicate that cancers re-emerge once SERM treatment is
ceased (Table 1 and Figure 1). That these re-emergent
cancers and underlying precancerous lesions retain func-
tional ERa (Figure 4) and respond to retreatment with ral-
oxifene (Table 3) indicates that most of the recurrent
neoplastic disease is not a consequence of acquired resis-
tance to raloxifene. Consistent with this conclusion, main-
taining mice on continuous raloxifene treatment prevented
re-emergence of disease (Table 3). If applicable to
women, these results provide insight into areas of optimi-
zation and improvement for the treatment of HPV-
associated cervical cancers using SERMs, which may
represent a potential breakthrough for a disease that has few
treatment options.
The ﬁnding that lower reproductive tract cancers recur
after cessation of raloxifene therapy was not completely
unanticipated; however, the extent to which recurrent tu-
mors re-emerged within 3 months was surprising because
we could not histopathologically detect remnants of cervical
cancer after the initial raloxifene treatment in the vast ma-
jority of mice (Table 1). We were able to discount the
possibility that the cancers arising after cessation of ralox-
ifene treatment arose through de novo tumorigenesis, given
that cancer incidence was negligible in the NoE26m/Ral1m/
E23m control group. Therefore, neoplastic cells that arose
during the initial 6-month treatment with estrogen and
before raloxifene treatment must have been preserved and
were subsequently responsible for the re-emergence of
neoplastic disease. This re-emergent neoplastic disease was
as follows: i) more severe in mice retreated with exogenous
estrogen (Table 1), ii) retained functional ERa (Figure 4),
and iii) remained dependent on ERa function because
retreatment with raloxifene caused the regression of this
disease (Table 3). The latter indicates that the disease
recurrence is not a consequence of acquired resistance to
raloxifene. Consistent with this conclusion, re-emergence ofThe American Journal of Pathology - ajp.amjpathol.orgneoplastic disease was prevented by sustained treatment
with raloxifene (Table 3). Furthermore, our data indicate
that the recurrent disease retains its dependence on estrogen
signaling, even if it is only endogenous estrogen that is
available. Yet, it appears that the neoplasia recurred rapidly
when one considers that the time it took the female repro-
ductive tract to regain responsiveness to estrogen after
cessation of raloxifene treatment was substantial (8 to 10
weeks), therefore leaving only 2 to 4 weeks during which
the estrogen was actively stimulating ERa function.
Consequently, the question remains as to how recurrent
neoplastic disease reappears so quickly when our experience
with the K14E6/E7 transgenic mouse model indicates that
such a short period of estrogen exposure is unlikely to
promote complete neoplastic progression.
One possibility is that the persisting neoplastic cells ac-
quired as-yet-identiﬁed properties that make them highly
aggressive in their growth once estrogen signaling in the
tissue was restored. That those mice with recurrent tumors
had more hyperproliferative cervical/vaginal epithelium
than mice without recurrent tumors (Figure 2) might suggest
that the remaining malignant cells that facilitate the recur-
rence of cancers are expressing paracrine factors that pro-
mote rapid growth. Alternatively, these mice may have
some inherent difference (not genetic, because these are
inbred mice) that predisposes them to the re-emergence of
disease. This difference could be as simple as the time it
took for raloxifene to wash out of their reproductive tracts.
The location of recurrent tumors may also reveal insight
into what contributes to recurrent disease. Regardless of
whether the mice were treated with exogenous estrogen,
cervical tumors arose almost exclusively within the outer
cervix and cervicovaginal region and rarely developed in the
transformation zone. Interestingly, our laboratory found that
cervical cancers in K14E6/E7 mice were more likely to
persist in the cervicovaginal junction and outer cervix than
in the cervix proper when the initial 6-month exogenous
estrogen treatment was followed with a 3-month period of
estrogen withdrawal.16 Although the molecular mechanisms
for this ﬁnding remain poorly understood, one hypothesis is
that this anatomical location of the reproductive tract is
more permissive for tumor growth. Qualitative observations
made throughout the study presented herein support this
hypothesis. In our analysis of cellular proliferation in the
cervical epithelium presented in Figure 2, we observed that
epithelial cells in the outer cervix had a higher level of BrdU
incorporation than those in the endocervix and trans-
formation zone in all mice (data not shown). Moreover,
when we analyzed the amount of time required for estrogen
responsiveness to reappear after raloxifene treatment
(Supplemental Figure S1), the outer cervix and vagina
contained PRþ cells several weeks before the endocervix
and transformation zone (data not shown). Taken together,
the BrdU and PR IHC data indicate that there are various
levels of proliferation and estrogen sensitivity within
different areas of the cervix. These qualitative assessments539
Spurgeon et alsuggest that the outer cervix and cervicovaginal region may
be more proliferative and more sensitive to estrogen than the
cervix proper and may help explain why we see a prepon-
derance for recurrent tumor development in the outer cervix.
Perhaps these observations help explain the apparently rapid
onset of recurrent disease. For instance, it is possible that in
those regions where tumors recurred, estrogen function was
regained several weeks earlier, thus providing more time for
the expansion of persisting neoplastic cells.
Whether the recurrent neoplastic disease differs from the
original disease, the fact that maintaining the mice on ral-
oxifene was highly effective at preventing frequent recur-
rence provides important insight into any application of this
targeted therapy to the treatment of human cervical cancer.
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